Advertising

The Seattle Times Company

NWjobs | NWautos | NWhomes | NWsource | Free Classifieds | seattletimes.com

The Seattle Times

Business / Technology


Our network sites seattletimes.com | Advanced

Originally published Saturday, December 8, 2007 at 12:00 AM

E-mail article     Print view

Business Digest

Oust 2 Nautilus directors, advisory firms say

Pacific Northwest Top proxy advisory firms ISS and Glass Lewis have recommended Nautilus shareholders vote to remove directors Peter Allen...

Top proxy advisory firms ISS and Glass Lewis have recommended Nautilus shareholders vote to remove directors Peter Allen and Donald Keeble and replace them with nominees supported by dissident investor Sherborne Investors.

But the advisory firms said in reports issued this week that investors should not remove two other directors, Evelyn Follit and Diane Neal. If all four were replaced with the dissident directors, Sherborne would gain control of the board.

Both ISS and Glass Lewis acknowledge that the company's recent performance has been disappointing. Still, ISS said management has presented a detailed plan to improve the company's performance, while Sherborne has not laid out any specific solutions.

Nautilus stock rose 93 cents, or 15.3 percent, to $7 Friday after D.A. Davidson analyst Reed Anderson increased his share-price forecast for the maker of Bowflex and StairMaster exercise machines, citing the Vancouver, Wash., company's partnership with retailer Dick's Sporting Goods.

Seattle Genetics

Progress on drug triggers payment

Seattle Genetics said Friday it had begun a new midstage clinical trial for its SGN-40 anti-cancer therapy, triggering a $12 million milestone payment from research partner Genentech.

The Bothell company's drug will be tested on patients with relapsed or refractory diffuse large B-cell lymphoma, a type of immune-system cancer. The trial is expected to enroll about 200 patients, the company said in a statement.

Seattle Genetics, the area's second-largest independent biotech company, could receive up to $800 million in payments from Genentech upon hitting research and regulatory milestones, as well as sales royalties and refunds for research, development and other costs.

Dow Jones & Co.

Murdoch installs his own team

advertising

Rupert Murdoch installed his own leadership team at Wall Street Journal publisher Dow Jones & Co. on Friday, a week before his acquisition of the company is expected to close.

Les Hinton, who has spent his career at News Corp.'s newspapers, will become CEO of Dow Jones next week, after a Dec. 13 vote of shareholders.

Robert Thomson, editor of The Times of London, will become publisher of the Journal. Dow Jones also owns Dow Jones Newswires, Barron's and news database Factiva.

Compiled from Reuters, Bloomberg News and Seattle Times staff

Copyright © 2007 The Seattle Times Company

Nintendo re-enlists Mario, savior of video-game industry

Verizon-Frontier deal stirs concern among consumers

Brier Dudley: 'Guitar Hero' founder excited about future

NEW - 11:03 PM
Hutch gets $10M from Bezos family for immunotherapy research

Interface: Socrata helps public agencies share data

Advertising

Video

Raw Video | Real Salt Lake receives the MLS Cup trophy
Real Salt Lake is handed the 2009 MLS Cup trophy at Qwest Field, November 22, 2009.

Raw Video | Real Salt Lake fans celebrate
Real Salt Lake fans enter Qwest Field
Raw Video | MLS Cup Opening Ceremony
LA Galaxy's David Beckham
Real Salt Lake's Kyle Beckerman
MLS trophy arrives in Seattle
Chittenden Locks Inspection
Full interview with New Moon actors
Interview with New Moon actors

Marketplace

nwautos

2009's most fuel-efficient sedansnew
Choosing a new sedan? Weigh the impact of your choice on your wallet and on the planet.
Post a comment

Open Houses

Find this weekend's open house listings.
Or search by location:

 
Most read
Most commented
Most e-mailed
 
 
Advertising